Ivermectin for Cancer: What the Research Says About Its Potential
For many cancer patients, standard treatments like chemotherapy and radiation can be lifesaving. But what happens when those treatments don’t work or stop working?
That’s where a new wave of research is shining a light on an unexpected strategy: repurposing well-known medications drugs originally developed for other conditions that may have hidden potential in cancer care.
One of the most surprising candidates?
Ivermectin.
A decades-old antiparasitic drug known for its safety and global use.
Now, emerging studies suggest that this humble medication might have untapped potential to slow tumor growth, enhance chemotherapy, and even trigger cancer cell death in certain types of cancer.
👉 Curious how this plays out in real life? Read how Tim survived stage 4 cancer using repurposed drugs and fasting.
The Discovery of Ivermectin
Ivermectin was discovered in 1970 by Japanese microbiologist Satoshi Ōmura and Irish-American parasitologist William C. Campbell.
Their research on soil-derived bacteria led to the development of a powerful antiparasitic medication that has since been used worldwide in both human and veterinary medicine.
In recognition of this breakthrough, they were jointly awarded the Nobel Prize in Physiology or Medicine in 2015 for discoveries that transformed the treatment of parasitic diseases.
Today, ivermectin is one of several antiparasitic medications being explored in cancer research alongside drugs such as mebendazole and fenbendazole.
A 2020 study concluded that Ivermectin has powerful antitumor effects:
Promotes programmed cancer cell death
Reverse multidrug resistance
Exerts the optimal effect when used in combination with chemotherapy
How Ivermectin May Work in the Body
Researchers have been exploring whether ivermectin may influence biological processes involved in cancer growth and treatment response.
Some scientific reviews suggest the drug may affect the internal signaling systems that cancer cells use to grow, spread, and resist treatment.
For example, a recent review published in Pharmaceuticals found that ivermectin may interact with pathways linked to tumor survival, immune response, and the ability of cancer cells to multiply.
However, most of the available evidence comes from laboratory or early clinical research. Larger human studies are still needed to understand whether these biological effects translate into meaningful outcomes for patients.
For now, ivermectin remains an area of ongoing scientific investigation rather than a validated cancer treatment.
Ivermectin and Specific Cancer Types
The role of Ivermectin in various cancers has received some notoriety among scientists for its beneficial effects on cancer patients.
Benefits were studied for breast cancer also TNBC, digestive system cancer, ovarian, hematological, brain, melanoma, respiratory system cancer, and others.
In 2023 another study was done, this time in Loja Ecuador, that looked at the effects of Ivermectin on cancer patients when taken both as a stand alone treatment as well as a complimentary protocol with other standards of care.
Patients from both groups reported improvements in their health and general well-being.
Colorectal Cancer and Ivermectin: What Emerging Research Suggests
A study out of Henan University in China evaluated the application of ivermectin on colon cancer proliferation.
The results were that Ivermectin inhibited the proliferation of colon cancer cells by arresting the tumor cell cycle. It also changed the structure of the cells, making them weaker while also inducing apoptosis.
A more recent study, published in 2022, observed that Ivermectin in high doses triggered cell death (apoptosis) in colon tumor tissue. Notably, at medium and high concentrations, the drug demonstrated a protective effect by reducing damage to the colon tissue.
This video talks about new research into the potential effect of Ivermectin on Colon Cancer cells.
Ivermectin and Triple-Negative Breast Cancer: A Promising Combo Trial
Triple negative breast cancer, or TNBC, is a type of cancer that lacks or has low levels of three key receptors:
- Estrogen receptor
- Progesterone receptor
- Human epidermal growth factor receptor 2 (HER2).
This type of cancer typically has the worst prognosis and is among the most aggressive forms of breast cancer.
A current ivermectin cancer clinical trial is now done to test Ivermectin benefits for TNBC patients.
The assumption is that giving Ivermectin with Pembrolizumab may increase the drug’s effect in shrinking tumors.
The study is done on patients with triple-negative breast cancer, which has spread to other places in the body (metastatic).
It may help the body’s immune system attack cancer and interfere with the ability of tumor cells to grow and spread. Ivermectin may help block the formation of growths that may become cancer.
Ovarian Cancer: Ivermectin’s Potential as a Supportive Agent
Ivermectin has demonstrated a potential supplemental role in the treatment of ovarian cancer.
Ivermectin interacts with the newly discovered gene target KPNB1, to have an anti-tumor effect on epithelial ovarian cancer (EOC) cells.
It can also enhance the effectiveness of chemotherapy by targeting signaling pathways and preventing the development of cancer cells that rely on these pathways.
In 2023, a scientific study looked at two drugs, Ivermectin and Pitavastatin, a cholesterol-lowering drug, and their effect on ovarian cancer. When Ivermectin was used alone, it slowed down cell growth, but not very strongly.
However, when the two drugs were combined, Ivermectin worked synergistically with pitavastatin by inducing programmed cell death (apoptosis).
Can Ivermectin Help Fight Brain Tumors like Glioblastoma?
The most common primary malignant brain tumor, Glioma, is still incurable because no proven treatments exist.
Glioblastoma is the deadliest form of brain cancer with a median survival time of only 14 to 17 months.
Clinical trials however found that Ivermectin can greatly limit colony formation and proliferation in Glioblastoma cells.
These cells experience apoptosis, or “programmed cell death.”
Medical research also shows that Ivermectin induces cell cycle arrest and cell death in vitro and in vivo, which inhibits the proliferation of glioma cells and may be a promising treatment for the disease.
Ivermectin’s Role in Prostate Cancer
Studies have found that Ivermectin can stop the growth of prostate cancer cells and cause them to die.
It can also decrease the signaling of androgen receptor and slow down the progression of tumors in living organisms.
It was also found that Ivermectin (IVM) can improve the effectiveness of the anti-androgen drug enzalutamide in prostate cancer cells and reverse the resistance of prostate cancer cells to docetaxel.
Digestive System Cancers: Lab Studies Show Tumor Inhibition
One of the most prevalent malignant tumors in the world is gastric cancer.
In vivo and in vitro gastric cancer cell proliferation was greatly reduced by Ivermectin.
According to Nambara’s 2017 study, Ivermectin could be used as a YAP1 inhibitor to treat cancer. YAP1 has an oncogenic function (causes the development of tumors) in carcinogenesis.
Ivermectin and Melanoma: Exploring Activity Against Skin Cancer
The most prevalent malignant skin tumor and one with a high fatality rate is melanoma.
Studies revealed that clinicians who used IVM to treat melanoma cells discovered that it might successfully decrease malignant activity.
It’s interesting to note that IVM may also exhibit activity against wild-type melanoma cells.
Its administration in combination with other pharmacological treatments may substantially boost anticancer efficacy.
Leukemia and Blood Cancers: Could Ivermectin Offer a Targeted Approach?
In a study looking at potential treatments for leukemia, Ivermectin was found to be effective in killing leukemia cells at low concentrations while leaving healthy blood cells unharmed.
The plasma membrane became hyperpolarized due to IVM, which increased the number of chloride ions entering the cell and caused the generation of reactive oxygen species (ROS).
Furthermore, Ivermectin was found to be more effective in treating leukemia than the drugs Daunorubicin and Cytarabine.
Enhancing Chemotherapy: Ivermectin’s Possible Supportive Role
When combined with other chemotherapy drugs, Ivermectin has shown promising results in treating cancer.
It can inhibit the growth of tumor stem cells, reverse multidrug resistance, and hinder the growth of tumors.
Ivermectin induces a process called, apoptosis, which leads to cell death in cancer cells, while also regulating autophagy, which is the body’s natural process of cleaning out damaged cells.
Is There a Standard Ivermectin Dosage for Humans?
One of the most common questions patients ask is whether there is a standard ivermectin dosage for cancer.
At present, there is no universally accepted oncology dosage protocol.
Approved ivermectin dosing for parasitic conditions is typically based on:
- Body weight
- Clinical indication
- Duration of treatment
When ivermectin is explored in integrative cancer approaches, dosing strategies may differ depending on:
- Cancer type
- Combination therapies
- Patient health status
- Treatment goals
Because of these variables, patients are strongly advised not to self-medicate and to seek medical guidance from a qualified professional.
Potential Side Effects of Ivermectin
Eye discomfort or redness
Swollen eyes & vision issues
Skin irritation, itchiness, rash, or acute skin rash;
Bewilderment- a shift in your mental state
Issues with balance
Difficulty walking
Fever
Enlarged Glands
Discomfort in the stomach or joints
Swelling in the hands or feet
Rapid heartbeat and breathing difficulties
A lack of bowel or bladder control
Seizure (convulsions)
Neck ache
A sense of being dizzy and on the verge of passing out.
low blood pressure (hypotension)
What Forms of Ivermectin Exist?
Ivermectin is available in several formulations depending on how it is used in medical or veterinary settings.
The most commonly prescribed form for human use is oral ivermectin, typically used to treat certain parasitic infections.
Topical preparations, including creams to treat rosacea or lotions commonly used to treat head lice.
Clinical reviews note that ivermectin has been administered through both systemic and topical routes in human medicine, reflecting its broad therapeutic applications.
When ivermectin is discussed in integrative oncology contexts, the formulation, if used, can vary depending on a clinical assessment, treatment strategy, and any regulatory considerations in different countries.
Where To Buy Ivermectin?
People researching integrative or repurposed approaches often ask practical questions about where to buy ivermectin or whether it can be obtained over the counter.
In many regions, ivermectin formulated for human use requires a prescription and must be dispensed through licensed pharmacies.
Regulations, however, vary significantly between countries and healthcare systems.
Online forums and patient communities sometimes reference other sources, such as veterinary or agricultural supply retailers and international pharmacies.
Health authorities have cautioned that products intended for animals may differ in concentration, quality control, and dosing guidance compared with medications approved for human use.
Because of these variations, and the lack of standardized dosing for cancer-related use, patients are strongly encouraged to speak with a qualified healthcare professional before attempting to purchase or use ivermectin in any form.
Key Takeaways
The potential of Ivermectin as an anticancer drug is still being explored, and the current research suggests promising results in various types of cancers.
Ivermectin’s ability to induce cell cycle arrest and apoptosis, inhibit tumor progression, and enhance the activity of other cancer drugs makes it an attractive candidate for further investigation.
While more studies are needed to fully understand the mechanism of action and optimal dosage for cancer treatment, the safety and availability of ivermectin make it an attractive option for clinical trials.
It’s important to note that Ivermectin is not currently approved for cancer treatment by regulatory agencies, and patients should not self-medicate without proper medical supervision.
However, with continued research and clinical trials, Ivermectin may prove to be a valuable addition to the arsenal of cancer-fighting drugs.
Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
